Baird Medical Champions Global Collaboration in Microwave Ablation at International Thyroid Workshop

Rhea-AI Summary

Baird Medical (NASDAQ: BDMD) participated in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism held in Beijing on October 17-18, 2025 at the China-Japan Friendship Hospital.

Chaired by Prof. Ming'an Yu, the workshop featured live procedures, clinical exchanges, and advanced technique discussions. Baird Medical said its presence highlights a commitment to international collaboration, sharing best practices for Microwave Ablation (MWA), and advancing minimally invasive thyroid care.

NEW YORK, Oct. 20, 2025 /PRNewswire/ -- Baird Medical Investment Holdings Ltd. (NASDAQ: BDMD), a global leader in minimally invasive Microwave Ablation (MWA) technology, today announced its participation in the 3rd International Workshop on Thermal Ablation of Thyroid Tumor and Hyperparathyroidism. The prestigious academic event was hosted by the China-Japan Friendship Hospital in Beijing, China, from October 17-18, 2025.

Chaired by Prof. Ming'an Yu, a leading authority in interventional medicine, the workshop served as a vital platform for the world's foremost experts to share clinical experience, discuss advanced techniques, and observe live procedures.

Baird Medical's presence at the workshop underscores its commitment to fostering international dialogue and advancing the global standard of care. The event provided a unique opportunity for a direct exchange of knowledge and best practices among top practitioners, fostering an environment of shared learning and innovation.

"We're honored to join this pivotal workshop and help connect the global medical community," said Haimei Wu, Chairwoman of Baird Medical. "Meaningful progress in medicine comes through collaboration. By uniting leading experts worldwide, we advance MWA innovation and accelerate best practices to improve patient care. Our mission is to empower physicians shaping the future of minimally invasive treatment."

The workshop underscores a growing international consensus on the benefits of MWA as a safe and effective, non-surgical treatment for thyroid conditions, and Baird Medical is proud to be at the forefront of this global movement.

About the ACS Clinical Congress
The American College of Surgeons (ACS) Clinical Congress is one of the world's largest gatherings of surgeons, dedicated to sharing advancements in surgical techniques and improving patient care. The congress brings together thousands of professionals from across the globe to exchange knowledge and foster collaborations that advance clinical practices.

About Baird Medical

Baird Medical is a forward-thinking medical device company specializing in minimally invasive diagnostics and treatment. It is dedicated to the research and development of surgical robotic systems and innovative minimally invasive surgical instruments. Our mission is to enhance patient outcomes through precision technology and advanced diagnostic solutions. The company will foster strategic collaborations with leading academic institutions. Our vision extends beyond surgical assistance, aiming to develop intelligent systems that proactively guide diagnostic decisions and preventive healthcare strategies. As an FDA 510(k)-certified medical device company, Baird Medical's solutions have been used in over 30 prestigious hospitals and clinics across the United States, including Johns Hopkins Hospital, Tulane Medical Center, Weill Cornell Medicine, and Columbia University Medical Center. Baird Medical is also the market leader in China in thyroid microwave ablation devices and consumables. Meanwhile, the company's minimally invasive treatment products are gradually expanding their commercial presence in over 20 countries worldwide.

Forward-Looking Statements

This press release includes certain statements that are not historical facts but are forward-looking statements for purposes of the safe harbor provisions under the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements generally relate to future events or Baird Medical's future financial or operating performance. In some cases, you can identify forward-looking statements by terminology such as "may", "could", "should", "expect", "intend", "might", "will", "estimate", "anticipate", "believe", "budget", "forecast", "intend", "plan", "potential", "predict", "potential" or "continue", or the negatives of these terms or variations of them or similar terminology. Forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Baird Medical and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. You should not place undue reliance on forward-looking statements in this press release, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Baird Medical does not undertake any duty to update these forward-looking statements.

Actual results may vary materially from those expressed or implied by forward-looking statements based on a number of factors, including, without limitation: (1) the risk that Baird Medical may not be successful in expanding its business in China or the United States; (2) changes in general economic conditions; (3) regulatory conditions and developments; (4) changes in applicable laws or regulations; (5) the nature, cost and outcome of pending and future litigation and other legal proceedings instituted against Baird Medical or others; and (5) other risks and uncertainties from time to time described in the Registration Statement relating to the Business Combination and the transition report, including those listed under the sections titled "Risk Factors" therein, and in ExcelFin's other filings with the SEC. 

The foregoing list of factors is not exclusive. Additional information concerning certain of these and other risk factors is contained in ExcelFin's most recent filings with the SEC and in the Registration Statement described above filed by Baird Medical in connection with its business combination with ExcelFin. All subsequent written and oral forward-looking statements concerning Baird Medical, the business combination described herein or other matters attributable to Baird Medical or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements above. Readers are cautioned not to place undue reliance upon any forward-looking statements, which speak only as of the date made. Baird Medical expressly disclaims any obligations or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in their expectations with respect thereto or any change in events, conditions or circumstances on which any statement is based.

Contact:
Eric Huang, PR Liaison
Baird Medical Investment Holdings Ltd.
Phone: +1 (888) 508-6228
Email: ir@bairdmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/baird-medical-champions-global-collaboration-in-microwave-ablation-at-international-thyroid-workshop-302588746.html

SOURCE BDMD

FAQ

What did Baird Medical (BDMD) announce about the October 2025 Beijing workshop?

Baird Medical said it participated in the 3rd International Workshop on Thermal Ablation in Beijing on October 17-18, 2025 to share clinical experience and observe live MWA procedures.

Where and when was the 3rd International Workshop on Thermal Ablation that BDMD attended?

The workshop took place at the China-Japan Friendship Hospital in Beijing on October 17-18, 2025.

Who chaired the workshop Baird Medical attended and what was covered?

The event was chaired by Prof. Ming'an Yu and covered clinical experience, advanced MWA techniques, and live procedures.

How did Baird Medical describe the significance of its participation in the workshop?

Baird Medical said its participation underscores a commitment to international dialogue, advancing MWA innovation, and accelerating best practices to improve patient care.

Does the workshop announcement for BDMD include financial or commercialization details?

No; the announcement focuses on clinical collaboration and knowledge exchange and does not disclose financial or commercial metrics.

What is Microwave Ablation (MWA) in the context of Baird Medical's announcement (BDMD)?

MWA is described as a minimally invasive, non-surgical treatment for thyroid conditions that the workshop discussed as a safe and effective option.